Clinical Trial Update: A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TAR-200 to intravesical chemotherapy in patients with recurrent high-risk non-muscle-invasive bladder cancer after BCG treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• TAR-200

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING